Investors
Corporate Profile
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic and autologous CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.
Stock Information
Financial Market Data powered by Quotemedia. All rights reserved.
View the Terms of Use. Data delayed 15 minutes unless indicated.
ISIN: BE0974260896-XBRU Updated at
Financial Calendar
March 24, 2022
FY 2021 Financial Results
May 5, 2022
Q1 2022 Financial Results
August 5, 2022
H1 2022 Financial Results
Nov 10, 2022
Q3 2022 Financial Results
Investors Kit
Corporate Presentation
Corporate Fact Sheet
Annual Report 2021
Upcoming Events
10
Nov
2022
Third Quarter 2022 Financial Results
